| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.5 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.036 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.033 | 0.6 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |